drugset / Trial / NCT06622824
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
Phase 2/3
Not yet recruiting
756 enrolled
Suzhou Kintor Pharmaceutical Inc
Suzhou Koshine Biomedica, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA). It consisted of two phases, phase 2 dose exploration trial and phase 3 confirmatory trial.
Timeline
- Start
- 2024-10-15
- Primary completion
- 2027-10-20
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KX-826 | Unknown | 0.5 % | Topical |
| Subject | KX-826 | Unknown | 1 % | Topical |